Pharmacokinetics of idarubicin (4‐demethoxydaunorubicin; IMI‐30; NSC 256439) following intravenous and oral administration in patients with advanced cancer.

Open Access
Publisher Website
Google Scholar
Abstract
The plasma pharmacokinetics of idarubicin (4‐demethoxydaunorubicin) were studied in 20 patients with advanced malignant disease after intravenous (21 occasions) and oral (14 occasions) administration. Idarubicin plasma concentrations were measured by high performance liquid chromatography with fluorescence detection. Pharmacokinetic parameters calculated for the intravenous plasma drug concentration, time data revealed a terminal half‐life of 12.9 +/‐ 6.0 h (mean +/‐ s.d.), clearance 98.7 +/‐ 47.3 1 h‐1 m‐2 and volume of distribution 1533 +/‐ 536 1 m‐2. A bi‐exponential equation corresponding to a two compartment open model best fitted the data. Half‐life and clearance were not significantly different following oral administration. Bioavailability of oral idarubicin was 0.29 +/‐ 0.20 (mean +/‐ s.d.). There was a wide range of bioavailability between and within subjects. Plasma concentrations of idarubicinol (the only metabolite detected) rapidly exceeded those of the parent drug, and exposure to this metabolite was greater than to the parent drug. The mean half‐life of idarubicinol was not significantly different after i.v. (63.1 +/‐ 28.2 h) and oral (45.8 +/‐ 16.0 h) administration. Much larger amounts of this metabolite were formed following the oral route of administration. This may have implications for the clinical use of this drug as idarubicinol may have appreciable cytotoxic activity.